Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Hematologic Neoplasms × enasidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1

Interventions

talquetamab 2 ivosidenib 1 fedratinib 1 enasidenib 1 Midazolam 1 Itraconazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Celgene

Phase 1/2 Completed

345 enrolled 120 charts 1 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡